Biotechnology

Can-Fite BioPharma

Can-Fite BioPharma Receives Patent Allowance Notification for CF602 in Brazil

Can-Fite BioPharma released FY2025 Q2 earnings on August 28, 2025 (EST), actual revenue USD 101K (forecast USD 0), actual EPS USD -0.2142 (forecast USD -0.12)

Can-Fite BioPharma released FY2025 Semi-Annual Earnings on August 28 (EST), actual revenue USD 202K, actual EPS USD -0.4287

Can-Fite BioPharma released FY2025 Q1 earnings on August 28 (EST), actual revenue USD 101K (forecast USD 0), actual EPS USD -0.2142 (forecast USD -0.12)

Can-Fite BioPharma's Namodenoson Progresses in Pancreatic Cancer Phase IIa Study

Can-Fite BioPharma Raises Funds for Drug Clinical Trials

Can-Fite BioPharma Obtains FDA Breakthrough Therapy Designation for Pancreatic Cancer Drug

Can-Fite BioPharma Seeks FDA Compassionate Use Approval for Namodenoson

Can-Fite BioPharma released FY2024 Q3 earnings on April 14 (EST), actual revenue USD 179 K (forecast USD 150 K), actual EPS USD -0.2325 (forecast USD -0.24)

Can-Fite BioPharma released FY2024 Q4 earnings on April 14 (EST), actual revenue USD 179 K (forecast USD 150 K), actual EPS USD -0.2325 (forecast USD -0.25)

Can-Fite BioPharma released FY2024 annual earnings on April 14, 2025 (EST), actual revenue USD 674 K (forecast USD 500 K), actual EPS USD -1.0863 (forecast USD -1.22)

Can-Fite BioPharma released FY2024 9 Months Earnings on April 14 (EST), actual revenue USD 495K, actual EPS USD -0.8841

Can-Fite BioPharma Releases 2024 Financial Results and Drug Progress

Can-Fite BioPharma Initiates Critical Phase III Study for Piclidenoson Targeting Psoriasis

Can-Fite BioPharma and Vetbiolix Launch Clinical Trial for Piclidenoson, Expected Market Size to Reach $6.3 Billion by 2030

Can-Fite BioPharma Receives FDA Approval for Compassionate Use of Namodenoson

Can-Fite BioPharma released FY2023 Q2 earnings on August 31 (EST), actual revenue 196 K USD (forecast 200 K USD), actual EPS -0.4086 (forecast -0.725)

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

Reverse Stock Split

合股

Ex Date: 2026.01.05 (EST), 1-for-20 Reverse Stock Split

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap